Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rein TherapeuticsRNTX +1.71%31 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates RNTX with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Rein Therapeutics ranks worse than 74.58% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rein Therapeutics's Debt-to-Equity or its related term are showing as below:
RNTX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.15 Med: 0.01 Max: 0.51
Current: 0.48
During the past 11 years, the highest Debt-to-Equity Ratio of Rein Therapeutics was 0.51. The lowest was -0.15. And the median was 0.01.
RNTX's Debt-to-Equity is ranked worse than 74.58% of 960
companies
in the Biotechnology industry
Industry Median: 0.155
vs RNTX: 0.48
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rein Therapeutics Debt-to-Equity Related Terms
Rein Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Rein Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNTX vs BSEM, OSTX, SPRO: Debt-to-Equity Comparison
For the Biotechnology subindustry, Rein Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rein Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rein Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rein Therapeutics (RNTX) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rein Therapeutics and its competitors. According to the industry distribution chart, Rein Therapeutics ranks #716 out of 960 companies in the Biotechnology industry, placing it in the top 74.6%.
Is Rein Therapeutics' Debt-to-Equity too high?
Rein Therapeutics' current Debt-to-Equity is 0.00. Based on the distribution chart, Rein Therapeutics ranks #716 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rein Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Debt-to-Equity compare to BSEM and OSTX?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #716 out of 960 companies for Debt-to-Equity. This places Rein Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rein Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rein Therapeutics's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Rein Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
31GF Score
Get the complete analysis for RNTX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNTX has been successfully added to your 
